Literature DB >> 12799509

Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings.

Noga Givon-Lavi1, Drora Fraser, Ron Dagan.   

Abstract

AIM: We conducted a study to determine whether administration of a pneumococcal conjugate vaccine to toddlers attending day-care centers (DCCs) could prevent acquisition of Streptococcus pneumoniae of the vaccine serotypes (VT) by their younger siblings.
METHODS: In a double blind study, 262 DCC attendees ages 12 to 35 months were randomized to receive a 9-valent pneumococcal conjugate vaccine (PnCRM9; n = 132), or a control vaccine (meningococcus C vaccine; n = 130). It was planned to follow the groups for 2 years with monthly nasopharyngeal pneumococcal cultures during the first follow-up year and every 2 months during the second year. Forty-six younger siblings of the above described children, age <18 months (23 siblings of the PnCRM9 recipients and 23 of the controls), were also enrolled, and nasopharyngeal cultures were obtained monthly until the children reached the age of 18 months or started to attend DCC, if before the age of 18 months. Pneumococcal isolates were serotyped and tested for antibiotic susceptibility.
RESULTS: Of the 3748 cultures obtained from the DCC attendees, 2450 (65%) were positive for S. pneumoniae. Of 306 cultures obtained from the younger siblings, 151 (49%) were positive. Among the PnCRM9 recipients, cultures were significantly less frequently positive for the VT S. pneumoniae than among the controls (13% vs. 21%, respectively; P < 0.001). The same pattern was seen in the younger siblings of PnCRM9 recipients vs. the siblings of controls (21% vs. 34%, respectively; P = 0.017). The reverse trend was seen for non-VT strains in both the DCC attendees (44% vs. 34%, respectively; P < 0.001) and their younger siblings (19% vs. 13%, respectively; P = 0.15). There was a significant decrease in the carriage rate of antibiotic-resistant S. pneumoniae in both the PnCRM9 recipients and their younger siblings. The relative risks (and 95% confidence intervals) to carry S. pneumoniae penicillin-nonsusceptible, resistant to > or =1, > or =2 and > or =3 antibiotic categories among younger siblings of PnCRM9 recipients vs. siblings of controls were 0.47 (0.31 to 0.70), 0.49 (0.33 to 0.71), 0.46 (0.30 to 0.73) and 0.49 (0.21 to 1.17), respectively. When acquired, VT and antibiotic-resistant S. pneumoniae were carried for a significantly shorter period of time among siblings of PnCRM9 recipients than in siblings of controls.
CONCLUSION: The marked effect of PnCRM9 administration to DCC attendees on carriage of VT and antibiotic-resistant S. pneumoniae among their younger household close contacts demonstrates a herd effect of the vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799509     DOI: 10.1097/01.inf.0000069760.65826.f2

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  23 in total

Review 1.  Conjugate vaccines.

Authors:  A Finn; P Heath
Journal:  Arch Dis Child       Date:  2005-07       Impact factor: 3.791

2.  Regulatory disincentives for developing antibiotics for common indications.

Authors:  Guy W Amsden
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

3.  Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).

Authors:  Emilio Pérez-Trallero; Jose E Martín-Herrero; Ana Mazón; Celia García-Delafuente; Purificación Robles; Victor Iriarte; Rafael Dal-Ré; Juan García-de-Lomas
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 4.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 5.  Acute otitis media in children: association with day care centers--antibacterial resistance, treatment, and prevention.

Authors:  David Greenberg; Sigalit Hoffman; Eugene Leibovitz; Ron Dagan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 6.  What can children gain from pneumococcal conjugate vaccines?

Authors:  Heikki Peltola; Robert Booy; Heinz-Josef Schmitt
Journal:  Eur J Pediatr       Date:  2004-06-10       Impact factor: 3.183

7.  Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media.

Authors:  Isabelle Hau; Corinne Levy; Laurence Caeymaex; Robert Cohen
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

8.  Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience.

Authors:  Michael R Jacobs; Caryn E Good; Bernard Beall; Saralee Bajaksouzian; Anne R Windau; Cynthia G Whitney
Journal:  J Clin Microbiol       Date:  2008-01-30       Impact factor: 5.948

9.  Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.

Authors:  Carol A McClure; Michael W Ford; Jeff B Wilson; Jeff J Aramini
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-01       Impact factor: 2.471

10.  Between-strain competition in acquisition and clearance of pneumococcal carriage--epidemiologic evidence from a longitudinal study of day-care children.

Authors:  Kari Auranen; Juha Mehtälä; Antti Tanskanen; Margit S Kaltoft
Journal:  Am J Epidemiol       Date:  2009-12-06       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.